CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) An isolated compound denoted 3,1'-didehydro-3 [2" (3'", 3'"- dimethyl – prop – 2 - enyl) - 3"- indolyl methylene]-6 - methylpiperazine-2,5-dione ~~extracted from a mangrove-associated fungus *Penicillium chrysogenum* having antibacterial activity~~, represented by a general formula $C_{19}H_{21}O_2N_3$ and having the structural formula as shown in Figure 1.



2. (Originally presented) A method for treating a *Vibrio cholerae* infection in a patient in need of treatment thereof, comprising the administration of an effective, antimicrobial amount of a compound as claimed in claim 1, ~~wherein the said compound shows antibacterial activity against the human pathogen *Vibrio cholerae*~~.

3. (Currently Amended) A process ~~of isolation of~~ for isolating 3,1'-didehydro-3 [2" (3'", 3'"- dimethyl – prop – 2 - enyl) - 3"- indolyl methylene]-6 - methylpiperazine-2,5-dione, having a structure as shown in Figure 1



from a fungus *Penicillium chrysogenum*, said process comprising the steps:

a) growing *Penicillium chrysogenum* in a fermentation broth comprising potato dextrose agar, sea water and distilled water;

b) extracting the fermentation broth with a solvent to obtain the filtrate;

c) evaporating the filtrate of step (b) to obtain a crude extract;

d) isolating the impure chrysogenazine from the crude extract of step (c) by chromatographic fractionation, and

e) purifying the impure chrysogenazine of step (d) using gel chromatography to obtain the pure chrysogenazine.

4. (Originally presented) A process as claimed in claim 3, wherein in step (a), seawater and distilled water is mixed in 1:1 ratio.

5. (Currently Amended) A process as claimed in claim 3, wherein in step (b), the solvent is selected from ~~a group comprising of~~ chloroform and or ethyl acetate.

6. (Originally presented) A process as claimed in claim 5, wherein the solvent is chloroform.

7. (Originally presented) A process as claimed in claim 3, wherein in step (c), the evaporation is performed under vacuum.

8. (Originally presented) A process as claimed in claim 3, wherein in step (d), the chromatographic fractionation is performed by column chromatography and thin layer chromatography.

9. (Originally presented) A process as claimed in claim 8, wherein silica gel chromatography is used for fractionation.

10. (Originally presented) A process as claimed in claim 9, wherein in silica gel chromatography the eluent used is mixture of petroleum ether and ethyl acetate.

11. A process as claimed in claim 9, wherein in the chromatography the adsorbent used is silica gel with a pore size of 60-120Å.

12. (Originally presented) A process as claimed in claim 3, wherein in step (e), the adsorbent used in gel chromatography is Sephadex LH-20.

13. (Originally presented) A process as claimed in claim 3, wherein in step (e), chloroform and methanol mixture is used as an eluent in gel chromatography.

14. (Originally presented) A process as claimed in claim 13, wherein the chloroform and methanol are mixed in 1:1 ratio.

15. (Originally presented) A process as claimed in claim 13, wherein *Penicillium chrysogenum* is *Penicillium chrysogenum*, bearing accession No. MTCC 5108.

16. (New) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.